VIVUS Qsymia Q4 patients beter but revenues below Street, says Credit Suisse Credit Suisse said Qsymia Q4 prescription numbers are better than expected but revenues are likely to come in below consensus. The firm rates shares an Outperform with a $16 price target.
News For VVUS From The Last 14 Days
Check below for free stories on VVUS the last two weeks.
Orexigen Contrave could have stronger launch than peers, says Wells Fargo After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.